CTI BioPharma Corp. (CTIC): What Does Valuation Ratios Tell Us?

BEPC Stock
BEPC Stock

CTI BioPharma Corp. (NASDAQ:CTIC) saw a downside of -2.49% to close Tuesday at $5.49 after subtracting -$0.14 on the day. The 5-day average trading volume is 1,851,800 shares of the company’s common stock. It has gained $5.76 in the past week and touched a new high 3 times within the past 5 days. An average of 2,505,740 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 3,206,490.

CTIC’s 1-month performance is -5.18% or -$0.30 on its low of $5.32 reached on 12/19/22. The company’s shares have touched a 52-week low of $1.82 and high of $7.80, with the stock’s rally to the 52-week high happening on 08/05/22. YTD, CTIC has achieved 121.37% or $3.01 and has reached a new high 23 times. However, the current price is down -29.62% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Insider Transactions

CTIC stock investors last saw insider trading activity on Nov 10.Craig Adam R (President and CEO) most recently sold 188,304 shares at $6.00 per share on Nov 10. This transaction cost the insider $1,130,703. President and CEO, Craig Adam R, sold 53,996 shares at a price of $6.00 on Nov 09. Then, on Nov 08, Director Metzger Michael A sold 91,500 shares at a price of $5.58 per share. This transaction amounted to $511,019.

Valuation Metrics

CTIC stock has a beta of 0.87. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 21.44.

CTI BioPharma Corp.’s quick ratio for the period ended June 29 was 3.20, with the current ratio over the same period at 3.30.. In terms of profitability, the gross margin trailing 12 months is 92.90%.

Earnings Surprise

For the quarterly period ending June 29 this year, CTI BioPharma Corp.’s cash and short-term investments amounted to $49.59 million against total debt of $109.02 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -53.91% to -$15.71 million, while revenue of -$22.65 million was -44.18% off the previous quarter. Analysts expected CTIC to announce -$0.2 per share in earnings in its latest quarter, but it posted -$0.21, representing a -5.00% surprise. EBITDA for the quarter stood at more than -$11.69 million. CTIC stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 140.3 million, with total debt at $109.02 million. Shareholders hold equity totaling $126.89 million.

Let’s look briefly at CTI BioPharma Corp. (CTIC) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 27 December was 42.47% to suggest the stock is trending Neutral, with historical volatility in this time period at 42.06%.

The stock’s 5-day moving average is $5.62, reflecting a +1.48% or $0.08 change from its current price. CTIC is currently trading -0.36% above its 20-day SMA, -24.69% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +17.31% and SMA200 by+19.61%.

Stochastic %K and %D was 37.09% and 44.76% and the average true range (ATR) pointed at 0.27. The RSI (14) points at 46.08%, while the 14-day stochastic is at 23.94% with the period’s ATR at 0.29. The stock’s 9-day MACD Oscillator is pointing at -0.04 and -0.06 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for CTI BioPharma Corp. (NASDAQ: CTIC), SVB Leerink launched coverage with an Outperform rating. Analysts offering their rating for CTIC stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate CTIC as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 9 have offered a “buy” rating.

What is CTIC’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $8.70 and a high of $15.00, with their median price target at $10.00. Looking at these predictions, the average price target given by analysts is for CTI BioPharma Corp. (CTIC) stock is $11.08.


Please enter your comment!
Please enter your name here